The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
Diagnostics · 26.10.2023 · 13 (21) · 3316
DOI: 10.3390/diagnostics13213316 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 26.10.2023. Verfasst von Teodora Biciusca und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Diagnostic and Interventional Radiology, Goethe University Hospital Frankfurt, 60596 Frankfurt am Main, Germany. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Currently, non-alcoholic fatty liver disease is the most common liver disease worldwide, with a prevalence of 32%. It is much more common among men (40%) and among patients with metabolic comorbidities such as obesity, diabetes and dyslipidemia. Being an asymptomatic disease, the diagnosis is often established on the basis of imaging methods, with an important role given to abdominal ultrasonography, computed tomography and magnetic resonance imaging. In order to facilitate diagnosis, experts have introduced a series of blood biomarkers. Two biomarker panels are currently validated for the diagnosis of non-alcoholic fatty liver disease: the fatty liver index, and the hepatic steatosis index. The fatty liver index has been in use in medical practice for over 17 years and has demonstrated its accuracy in various studies that compared it with other diagnostic methods, highlighted its role in screening patients with cardiovascular risk and validated the effects of different diets and drugs that are proposed for the treatment of the disease. In the management of non-alcoholic fatty liver disease, the fatty liver index is an important algorithm in the diagnosis and prognosis of patients with metabolic risk. Taking into account the diversity of drugs to be approved in the treatment of non-alcoholic fatty liver disease, the fatty liver index will become an effective tool in monitoring the effects of these therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Diagnostic and Interventional Radiology, Goethe University Hospital Frankfurt, 60596 Frankfurt am Main, Germany.
- Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Pneumology, Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania.
- Department of Internal Medicine, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Bacteriology-Virology-Parasitology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Pathophysiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
ORCID-Profile: Alice Elena Ghenea, Ana-Maria Bumbea, Viorel Biciusca
Zitieren
APA
Biciusca, T., Stan, S. I., Balteanu, M. A., Cioboata, R., Ghenea, A. E., Danoiu, S., Bumbea, A. M., & Biciusca, V. (2023). The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review. Diagnostics, 13(21), 3316. https://doi.org/10.3390/diagnostics13213316
Vancouver
Biciusca T, Stan SI, Balteanu MA, Cioboata R, Ghenea AE, Danoiu S, et al. The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review. Diagnostics. 2023;13(21):3316. doi:10.3390/diagnostics13213316
BibTeX
@article{Biciusca2023,
author = {Biciusca, Teodora and Stan, Sorina Ionelia and Balteanu, Mara Amalia and Cioboata, Ramona and Ghenea, Alice Elena and Danoiu, Suzana and Bumbea, Ana-Maria and Biciusca, Viorel},
title = {The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {21},
pages = {3316},
doi = {10.3390/diagnostics13213316}
}
EUVIMED